CG Oncology, Inc. Quarterly Operating Income (Loss) in USD from Q1 2023 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
CG Oncology, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2023 to Q4 2024.
  • CG Oncology, Inc. Operating Income (Loss) for the quarter ending December 31, 2024 was -$38M, a 96.5% decline year-over-year.
  • CG Oncology, Inc. Operating Income (Loss) for the twelve months ending December 31, 2024 was -$115M, a 107% decline year-over-year.
  • CG Oncology, Inc. annual Operating Income (Loss) for 2024 was -$115M, a 107% decline from 2023.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2024 -$115M -$38M -$18.7M -96.5% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-28
Q3 2024 -$96M -$28.3M -$14.3M -101% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 -$81.7M -$25.9M -$13.5M -110% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 -$68.2M -$22.5M -$12.7M -131% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 -$55.4M -$19.4M Oct 1, 2023 Dec 31, 2023 10-K 2025-03-28
Q3 2023 -$14M Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$12.3M Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 -$9.72M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.